1. , . Latest advances in understanding preeclampsia. Science 2005; 308: 1592–4.
2. . World Health Report: Make every mother and child count. Geneva: World Health Organization; 2005.
3. . The relation between hydatid moles, relative ischemia of the gravid uterus and the placental origin of eclampsia. Am J Obstet Gynecol 1939; 37: 291–3.
4. , . Preeclampsia prevention and management. J Soc Gynecol Investig 2000; 7: 21–36.
5. , , . Pre-eclampsia. Lancet 2005; 365: 785–99.
6. . Diagnosis, prevention, and management of eclampsia. Obstet Gynecol 2005; 105: 402–10.
7. , , . An epidemiological study of the immunogenetic aetiology of pre-eclampsia. Br Med J (Clin Res Ed) 1986; 292: 372–4.
8. , , , . Effect of body mass index on pregnancy outcomes in nulliparous women delivering singleton babies. BMC Public Health 2007; 7: 168.
9. , , , et al. Obstetrical and neonatal outcomes in obese women. West Indian Med J 2007; 56: 421–6.
10. , , . The familial factor in toxemia of pregnancy. Obstet Gynecol 1968; 32: 303–11.
11. , , , , . A sister’s risk: family history as a predictor of preeclampsia. Am J Obstet Gynecol 2005; 193: 965–72.
12. , , et al. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med 2001; 344: 867–72.
13. , , et al. Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception. Lancet 1994; 344: 973–5.
14. , , . The interval between pregnancies and the risk of preeclampsia. New Engl J Med 2002; 346: 33–8.
15. , , , , . Changing paternity and time since last pregnancy; the impact on pre-eclampsia risk. A study of 547 238 women with and without previous pre-eclampsia. Int J Epidemiol 2001; 30: 1317–22.
16. , , et al. Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. Lancet 2002; 359: 673–4.
17. , , , , . Fetal vasculogenesis and angiogenesis in human placental villi. Acta Anat (Basel) 1989; 136: 190–203.
18. , , . Hofbauer cells in early human placenta: possible implications in vasculogenesis and angiogenesis. Placenta 2007; 28: 841–5.
19. , , , , . Human villous macrophage-conditioned media enhance human trophoblast growth and differentiation in vitro. Biol Reprod 2000; 62: 1075–83.
20. , , et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate: a strategy for successful endovascular invasion? J Clin Invest 1997; 99: 2139–51.
21. , , . The role of spiral arteries in the pathogenesis of pre-eclampsia. Obstet Gynecol Annu 1972; 1: 177–91.
22. , , . Morphological changes of the spiral arteries in the placental bed in relation to pre-eclampsia and fetal growth retardation. Br J Obstet Gynaecol 1981; 88: 876–81.
23. , , , , . A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994; 101: 669–74.
24. , , . Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype: one cause of defective endovascular invasion in this syndrome? J Clin Invest 1997; 99: 2152–64.
25. , , , , . Early embryonic demise: no evidence of abnormal spiral artery transformation or trophoblast invasion. J Pathol 2006; 208: 528–34.
26. , , , , . Late sporadic miscarriage is associated with abnormalities in spiral artery transformation and trophoblast invasion. J Pathol 2006; 208: 535–42.
27. , , , , . Invasive cytotrophoblasts manifest evidence of oxidative stress in preeclampsia. Am J Pathol 2000; 156: 321–31.
28. , . Oxidative stress reproduces placental abnormalities of preeclampsia. Hypertens Preg 2002; 21: 205–23.
29. . Maternal-placental interactions of oxidative stress and antioxidants in preeclampsia. Semin Reprod Endocrinol 1998; 16: 93–104.
30. , , . Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180: 499–506.
31. , , , . Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol 1998; 179: 80–6.
32. , , et al. Hypoxia/reoxygenation stimulates endothelial cells to promote interleukin-1 and interleukin-6 production: effects of free radical scavengers. Agents Actions 1992; 37: 134–9.
33. , , , , . Soluble tumor necrosis factor receptors and interleukin-6 levels in patients with severe preeclampsia. Obstet Gynecol 1996; 88: 420–7.
34. , , , , . Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia. Am J Obstet Gynecol 1994; 170: 1752–7; discussion 1757–9.
35. , , . Leptin, IL-10 and inflammatory markers (TNF-alpha, IL-6 and IL-8) in pre-eclamptic, normotensive pregnant and healthy non-pregnant women. Am J Reprod Immunol 2007; 58: 21–30.
36. , , et al. Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab 2005; 90: 4299–308.
37. , , et al. Human placental hypoxia-inducible factor-1alpha expression correlates with clinical outcomes in chronic hypoxia in vivo. Am J Pathol 2007; 170: 2171–9.
38. , , et al. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006; 291: R1085–93.
39. , , , , . Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in preeclamptic placentae. Placenta 2004; 25: 763–9.
40. , . Adriana and Luisa Castellucci Award lecture 2001. Hypoxia inducible factor-1: oxygen regulation of trophoblast differentiation in normal and pre-eclamptic pregnancies – a review. Placenta 2002; 23(Suppl A): S47–57.
41. , , et al. Hypoxia-inducible factor-1 transactivates transforming growth factor-beta3 in trophoblast. Endocrinology 2004; 145: 4113–8.
42. , . Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006; 312: 549–60.
43. , , et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435–9.
44. , , et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439–42.
45. , , et al. Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters. J Surg Oncol 2008; 98: 190–6.
46. , , et al. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. Faseb J 2007; 21: 1088–98.
47. , , , , . Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J Virol 1994; 68: 84–92.
48. , , , . VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice. Biochem Biophys Res Comm 2003; 301: 371–7.
49. , , , , . Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A 1991; 88: 9267–71.
50. , , et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 9: 936–43.
51. , , et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7: 575–83.
52. , , , . Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen – a review. Placenta 2000; 21(Suppl A): S16–24.
53. , , et al. Expression of vascular endothelial growth factor and placenta growth factor in human placenta. Biol Reprod 1997; 56: 489–94.
54. , , et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 2006; 12: 1065–74.
55. , , et al. Genetic deletion of placenta growth factor in mice alters uterine NK cells. J Immunol 2007; 178: 4267–75.
56. , . Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002; 1: 219–27.
57. , , et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. Embo J 2001; 20: 1223–31.
58. , , et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87: 3336–43.
59. , , et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities: implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996; 271: 17629–34.
60. , , et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 2001; 97: 785–91.
61. , , . Role of Flt-1 receptor tyrosine kinase in regulation of assembly of vascular endothelium. Nature 1995; 376: 66–7.
62. , , et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62–6.
63. , , et al. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentae from normal and complicated pregnancies. Mol Hum Reprod 2001; 7: 205–10.
64. , , et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642–9.
65. , , . Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 1999; 274: 584–94.
66. , , , , . Inhibition of TGF-beta 3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies. J Clin Invest 1999; 103: 1641–50.
67. , , , . TGF-beta superfamily expression and actions in the endometrium and placenta. Reproduction 2006; 132: 217–32.
68. , , et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 8: 345–51.
69. , , . A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 1999; 104: 1343–51.
70. , , et al. Endoglin regulates nitric oxide-dependent vasodilatation. Faseb J 2004; 18: 609–11.
71. , , , . Localization of endoglin, a transforming growth factor-beta binding protein, and of CD44 and integrins in placenta during the first trimester of pregnancy. Biol Reprod 1994; 51: 405–13.
72. , , Preeclampsia and angiogenic imbalance. Ann Rev Med 2008; 59: 61–78.
73. , , et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998; 59: 1540–8.
74. , , et al. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 1998; 140: 947–59.
75. , . Circulating angiogenic factors in preeclampsia. Clin Obst Gynecol 2005; 48: 372–86.
76. , , et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649–58.
77. , , et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278: 12605–8.
78. , , et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707–716.
79. , , et al. VEGF inhibition and renal thrombotic microangiopathy. New Engl J Med 2008; 358: 1129–36.
80. , , , . Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186–93.
81. , , et al. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003; 101: 1266–74.
82. , , . Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta. Faseb J 2007; 21: 3885–95.
83. , , et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 2008; 102: 1566–74.
84. , , et al. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med 2008; 205: 491–501.
85. , , et al. Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta 1997; 18: 657–65.
86. , , et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004; 145: 4838–45.
87. , , . Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008; 93: 260–6.
88. , , et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 2007; 71: 977–84.
89. , , . Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 2007; 50: 1142–7.
90. , . Putting pressure on pre-eclampsia. Nat Med 2008; 14: 810–12.
91. , , et al. Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3. Am J Pathol 2008; 172: 77–85.
92. , , , , . Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta 2008; 29: 555–63.
93. , , et al. Placental expression of soluble fms-like tyrosine kinase 1 is increased in singletons and twin pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab 2008; 93: 285–92.
94. , , et al. Placental HIF-1 alpha, HIF-2 alpha, membrane and soluble VEGF receptor-1 proteins are not increased in normotensive pregnancies complicated by late-onset intrauterine growth restriction. Am J Physiol Regul Integr Comp Physiol 2007; 293: R766–74.
95. , , et al. Circulating angiogenic factors and the risk of preeclampsia. New Engl J Med 2004; 350: 672–83.
96. , , et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003; 88: 2348–51.
97. , , et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007; 50: 137–42.
98. , , et al. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007; 196:239. e231–236.
99. , , , . Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007; 49: 818–24.
100. , , et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008; 21: 9–23.
101. , , et al. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007; 197: e241–8.
102. , , et al. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 2008; 198: e171–6.
103. , , et al. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol 2007; 109: 1368–74.
104. , , et al. Urinary placental growth factor and risk of preeclampsia. Jama 2005; 293: 77–85.
105. , , et al. Evaluation of physiological alterations of the placenta through analysis of cell-free messenger ribonucleic acid concentrations of angiogenic factors. Am J Obstet Gynecol 2008; 198: e121–7.
106. , , . Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129 290 births. Lancet 2001; 357: 2002–6.
107. , , et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003; 326: 845.
108. , , , . Adverse perinatal outcome and later kidney biopsy in the mother. J Am Soc Nephrol 2006; 17: 837–45.
109. , , , , . Preeclampsia and the risk of end-stage renal disease. New Engl J Med 2008; 359: 800–9.
110. , , et al. Microalbuminuria after pregnancy complicated by pre-eclampsia. Nephrol Dial Transplant 1999; 14: 1129–32.
111. , , et al. Manifestations of metabolic syndrome after hypertensive pregnancy. Hypertension 2004; 43: 825–31.
112. , , et al. Early occurrence of metabolic syndrome after hypertension in pregnancy. Obstet Gynecol 2005; 105: 1373–80.
113. , , et al. Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab 2004; 89: 6239–43.
114. , , et al. Fetal nutrition and cardiovascular disease in adult life. Lancet 1993; 341: 938–41.
115. , , et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ 1991; 303: 1019–22.
116. , , , . Maternal size at birth and the development of hypertension during pregnancy: a test of the Barker hypothesis. Arch Intern Med 1999; 159: 1607–12.
117. , , et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007; 50: 686–92.
118. , . Placental ischemia and soluble fms-like tyrosine kinase 1: cause or consequence of preeclampsia? Kidney Int 2007; 71: 959–61.
119. , , et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3–18.